Stereotaxis to Acquire French Robotics Developer Robocath for up to $45 Million

Stereotaxis has entered into a definitive agreement to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions. The transaction includes an upfront payment of $20 million and additional contingent payments of up to $25 million tied to regulatory and commercial milestones, including FDA clearance of Robocath’s next-generation system. The acquisition combines Stereotaxis’ magnetic navigation technology with Robocath’s mechanical robotic system, creating a fully integrated robotic platform for endovascular procedures.

Robocath, headquartered in Rouen, France, has developed mechanical robotic technology for interventional cardiology and neurointerventions. Its R-One+ system is the only commercially available robotic solution for percutaneous coronary interventions in Europe, with fifteen systems installed globally. The company is also developing a next-generation system designed to enable simultaneous manipulation of up to five interventional devices, with initial first-in-human procedures recently completed in France. Stereotaxis plans to accelerate development of this next-generation system and pursue regulatory submissions in the United States and Europe within the next two years.

“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures,” said David Fischel, Stereotaxis Chairman and CEO. “By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine.” Philippe Bencteux, Founder and CEO of Robocath, added that joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate development and expand its impact. Stereotaxis estimates that Robocath will contribute approximately $2 million in annual revenue during the first year following the acquisition, with the deal expected to become breakeven by the third year. The acquisition is subject to customary closing conditions and is expected to close in mid-2026.